Hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the Silicon Valley Bank collapse and its impact on investing and innovation in the field of ophthalmology with Gilbert H. Kliman, MD.

·       Welcome to the Eyeluminaries podcast :01

·       Review of episode 12 with Richard L. Lindstrom, MD :30

·       Preview of episode 13 1:35

·       Gil Kliman, MD, introduction 2:36

·       History of Silicon Valley Bank 4:25

·       Silicon Valley Bank’s collapse 6:08

·       Guest welcome 8:07

·       Was the collapse a surprise? 8:22

·       Kliman on major themes of this event being how fast it happened and how unprecedented it was for companies 9:34

·       How many ophthalmic companies have been affected, and what are the next steps for these companies? 10:16

·       Kliman on the turning point when the FDIC stepped in on Sunday 11:50

·       Have you had companies report that they have accessed their funds at Silicon Valley Bank? 12:27

·       Kliman on his experience with Silicon Valley Bank 12:45

·       What should companies do going forward, and what are you advising companies? 14:17

·       Kliman on figuring out a new strategy and the unique issue of 90% of depositors being above the $250,000 FDIC threshold 16:13

·       What is the survival rate for small banks now? 17:31

·       What do you think the flavor of the room will be at Eyecelerator@ASCRS? 19:20

·       Kliman’s advice for companies to focus on burn rates 20:35

·       The physician’s perspective for supporting innovation and small business 21:54

·       How strategics can continue to partner with startups using their venture arm 24:04

·       Information on the Eyecelerator meeting 25:46

·       Wrap up and thank you, Gil 26:16

·       Feedback, questions and guest suggestions at [email protected] 26:45

·       Thanks for listening, and preview of episode 14 27:11 John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California.

Jim Mazzo is an ophthalmic industry veteran with over 40 years as CEO/Chairman of both public and private companies, including Allergan, Avellino Labs, Carl Zeiss, Neurotech Pharmaceuticals and AMO. Additionally, he is an advisor for Bain Capital and CVC Capital Partners and sits on numerous industry boards such as MDMA.

Gil Kliman, MD, is managing partner at InterWest Partners and is co-founder and program director of Eyecelerator.

We’d love to hear from you! Send your comments/questions to [email protected]. Follow John Hovanesian on Twitter @DrHovanesian.

Disclosures: Hovanesian consults widely in the ophthalmic field. Mazzo reports being an adviser for Zeiss, Bain Capital, Avellino Labs, CVC Capital, Anivive Lifesciences; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Crystilex, Lensgen, IanTech, Centricity Vision and Visus. Kliman is managing partner at InterWest Partners.